Inhibrx Biosciences (INBX) Revenue & Revenue Breakdown
Inhibrx Biosciences Revenue Highlights
Latest Revenue (Y)
$200.00K
Main Segment (Y)
License, Non-Affiliate
Inhibrx Biosciences Revenue by Period
Inhibrx Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $200.00K | -88.89% |
| 2023-12-31 | $1.80M | -17.36% |
| 2022-12-31 | $2.18M | -69.43% |
| 2021-12-31 | $7.13M | -44.37% |
| 2020-12-31 | $12.81M | 40.86% |
| 2019-12-31 | $9.09M | 21.24% |
| 2018-12-31 | $7.50M | -5.66% |
| 2017-12-31 | $7.95M | 19.24% |
| 2016-12-31 | $6.67M | - |
Inhibrx Biosciences generated $200.00K in revenue during NA 2024, up -88.89% compared to the previous quarter, and up 2.20% compared to the same period a year ago.
Inhibrx Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $100.00K | 100.00% |
| 2024-09-30 | - | -100.00% |
| 2024-06-30 | $100.00K | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.63M | 1273.11% |
| 2023-09-30 | $119.00K | 296.67% |
| 2023-06-30 | $30.00K | 76.47% |
| 2023-03-31 | $17.00K | -93.80% |
| 2022-12-31 | $274.00K | -1.44% |
| 2022-09-30 | $278.00K | -60.90% |
| 2022-06-30 | $711.00K | -22.30% |
| 2022-03-31 | $915.00K | -67.74% |
| 2021-12-31 | $2.84M | 13.08% |
| 2021-09-30 | $2.51M | 173.20% |
| 2021-06-30 | $918.00K | 6.37% |
| 2021-03-31 | $863.00K | -68.91% |
| 2020-12-31 | $2.78M | -52.35% |
| 2020-09-30 | $5.83M | 74.75% |
| 2020-06-30 | $3.33M | 282.34% |
| 2020-03-31 | $872.00K | 226.59% |
| 2019-12-31 | $267.00K | -66.37% |
| 2019-09-30 | $794.00K | -20.60% |
| 2019-06-30 | $1.00M | -85.78% |
| 2019-03-31 | $7.03M | 209.92% |
| 2018-12-31 | $2.27M | -9.24% |
| 2018-06-30 | $2.50M | - |
| 2018-03-31 | $2.50M | 789.68% |
| 2017-12-31 | $281.00K | - |
Inhibrx Biosciences generated - in revenue during Q1 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Inhibrx Biosciences Revenue Breakdown
Inhibrx Biosciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| License, Non-Affiliate | $200.00K | $1.80M | $2.18M | $10.81M | - |
| Grant | - | - | $14.00K | $86.00K | - |
| License | - | - | $2.18M | - | - |
| License, Affiliate - OX40 License Agreement | - | - | - | - | $2.00M |
| License, Affiliate - PD-L1 And 4-1BB License Agreement | - | - | - | - | - |
| License, Affiliate | - | - | - | - | $2.00M |
Latest
Inhibrx Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 24: License, Non-Affiliate (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 | Dec 24 | Jun 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License, Non-Affiliate | $1.30M | $1.30M | $100.00K | $100.00K | $1.75M | $30.00K | $17.00K | $278.00K | $711.00K | $915.00K | $2.51M | $918.00K | $863.00K | $3.83M | - | - | - |
| Grant | - | - | - | - | - | - | - | - | - | - | $14.00K | $20.00K | $24.00K | $36.00K | $26.00K | $300.00K | - |
| License | - | - | - | - | - | - | - | $274.00K | $2.84M | - | - | - | - | - | - | - | - |
| License, Affiliate - PD-L1 And 4-1BB License Agreement | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| License, Affiliate - OX40 License Agreement | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.00M |
| License, Affiliate | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.00M |
Latest
Inhibrx Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: License, Non-Affiliate (100.00%).
Inhibrx Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NKTR | Nektar Therapeutics | $98.43M | $11.79M |
| AMLX | Amylyx Pharmaceuticals | $87.37M | - |
| IMTX | Immatics | $54.00M | $30.45M |
| CVAC | CureVac | $52.70M | $12.37M |
| SNDX | Syndax Pharmaceuticals | $23.68M | $45.87M |
| RLAY | Relay Therapeutics | $10.01M | - |
| INBX | Inhibrx Biosciences | $200.00K | - |
| ATAI | Atai Beckley N.V | - | $749.00K |
| ELVN | Enliven Therapeutics | - | - |
| SANA | Sana Bio | - | - |
| ORIC | ORIC Pharmaceuticals | - | - |